A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Co., Ltd.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation
2. Participants treated with tazemetostat
You may not be if
1\. Participants with a history of hypersensitivity to any ingredient of Tazverik
Clareo Health | A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
